Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease
Journal Title: Annals of Hepatology - Year 2009, Vol 8, Issue 2
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries, and its prevalence is increasing worldwide. It currently affects approximately 30% of adults and 10% of children and adolescents. The resulting increase in the number of patients with NAFLD is expected to translate into increased numbers of patients with liver cirrhosis, and hepatocellular carcinoma. In this context, it is particularly important to identify patients at risk for progressive chronic liver disease. Currently, liver biopsy is the gold standard to diagnose non-alcoholic steatohepatitis (NASH) and to establish the presence and stage of fibrosis. Due to the remarkable increase in the prevalence of NAFLD and the concomitant efforts in developing novel therapies for patients with NASH, non-invasive, simple, reproducible, and reliable non-invasive methodologies are needed. This paper provides a concise overview of the role of non-invasive diagnostic tools for the determination of presence and extent of fibrosis in NAFLD patients, with particular emphasis on the methods currently available in clinical practice.
Authors and Affiliations
Francesco Vizzutti, Umberto Arena, Valerio Nobili, Roberto Tarquini, Marco Trappoliere, Giacomo Laffi, Fabio Marra, Massimo Pinzani
Keywords
Related Articles
- EP ID EP77848
- DOI -
- Views 106
- Downloads 0
Aminoguanidine potentiates the hepatoprotective effect of silymarin in CCL4 treated rats
This study examined the possible hepatoprotective effect of aminoguanidine in comparison with silymarin and investigated the possible beneficial effects of the combination of aminoguanidine and silymarin on CCL4-induced...
Hormone replacement therapy in menopausal women: risk factor or protection to nonalcoholic fatty liver disease?
No association of promoter variations of HMOX1 and UGT1A1 genes with liver injury in chronic hepatitis C
Background. Heme oxygenase-1 (HMOX1) and bilirubin UDP-glucuronosyltransferase (UGT1A1), both enzymes involved in bilirubin homeostasis, play an important role inoxidative stress defense. Objective. To assess the effect...
Cholestatic hepatitis C after chemotherapy containing rituximab in diffuse large B cell lymphoma
Rituximab is a chimeric anti-CD20 monoclonal antibody that is a widely used for the treatment of B cells non-Hodgkin lymphoma. The use of chemotherapy regimens containing rituximab in HCV-positive patients with non-Hodgk...
Treatment issues surrounding hepatitis C in renal transplantation: A review
Hepatitis C infection is prevalent in candidates for and recipients of solid organ transplants. In the renal transplant population, HCV infection has been shown to decrease long-term patient and graft survival. The outco...